These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9735117)

  • 21. Twenty years of HIV-1 research: what the future holds.
    Imami N; Gotch F
    Nat Immunol; 2003 Jun; 4(6):501. PubMed ID: 12774067
    [No Abstract]   [Full Text] [Related]  

  • 22. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection.
    de Goede AL; Vulto AG; Osterhaus AD; Gruters RA
    Ann Pharm Fr; 2015 Mar; 73(2):87-99. PubMed ID: 25496723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication of HIV-1 latent reservoirs through therapeutic vaccination.
    Pankrac J; Klein K; Mann JFS
    AIDS Res Ther; 2017 Sep; 14(1):45. PubMed ID: 28893280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of specific T-cell responses in HIV infection.
    Leandersson AC; Bratt G; Hinkula J; Gilljam G; Cochaux P; Samson M; Sandström E; Wahren B
    AIDS; 1998 Jan; 12(2):157-66. PubMed ID: 9468364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of preserving HIV-specific immune responses.
    Kaufmann DE; Rosenberg ES
    J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus infection, Part I.
    Horowitz HW; Telzak EE; Sepkowitz KA; Wormser GP
    Dis Mon; 1998 Oct; 44(10):545-606. PubMed ID: 9814367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunobiological aspects of HIV treatment.
    Dalgleish AG
    Curr Opin Immunol; 1993 Aug; 5(4):608-14. PubMed ID: 8105805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Paxton WB; Coombs RW; McElrath MJ; Keefer MC; Hughes J; Sinangil F; Chernoff D; Demeter L; Williams B; Corey L
    J Infect Dis; 1997 Feb; 175(2):247-54. PubMed ID: 9203644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination.
    Imami N; Hardy G; Burton C; Pires A; Pido-Lopez J; Moss R; Gazzard B; Gotch F
    Immunol Lett; 2001 Nov; 79(1-2):63-76. PubMed ID: 11595291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents.
    Wilson CC; Wong JT; Girard DD; Merrill DP; Dynan M; An DD; Kalams SA; Johnson RP; Hirsch MS; D'Aquila RT
    J Infect Dis; 1995 Jul; 172(1):88-96. PubMed ID: 7541065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in HIV-1 viral loads between male and female antiretroviral-untreated Mexican patients.
    Ballesteros-Zebadúa P; Villarreal C; Cocho G; Huerta L; Estrada JL
    Arch Med Res; 2013 May; 44(4):296-301. PubMed ID: 23608673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
    Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
    Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic vaccination for future management of HIV/AIDS.
    Lisziewicz J; Bakare N; Lori F
    Vaccine; 2003 Jan; 21(7-8):620-3. PubMed ID: 12531329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.